Kaletra(TM) (ABT-378/r) Early Access Program Can Accept More Patients

Kaletra(TM) (ABT-378/r) Early Access Program Can Accept More Patients

AIDS Treatment News Issue #349, August 18, 2000
John S. James

On August 4 Abbott Laboratories announced that its Early Access Program for the second-generation protease inhibitor Kaletra (formerly ABT-378/r) can accept more patients. Since January, the criteria have allowed access "to any HIV+ patient for whom Kaletra is necessary to construct a viable regimen, without CD4 cell count or viral load restrictions"-- the result of long negotiations with AIDS treatment activists in the Coalition for Salvage Therapy (CST). This drug continues to look good, mainly because blood levels achieved are much higher than needed to inhibit HIV replication-- allowing for individual variation in blood levels due to differences in absorption and metabolism, and also allowing the drug to inhibit some HIV mutants which would otherwise be resistant.

Some patients who have no approved drugs still effective for them choose to wait to start Kaletra until they can begin more than one experimental drug simultaneously.

From the August 4 release: "The Kaletra Early Access program is currently under way in 21 countries, and 6,100 patients are enrolled in the program, worldwide. Individuals interested in receiving Kaletra through early access should speak with their healthcare provider or call 1-888-711-7193 in the United States and Canada. Physicians who wish to request registration materials or additional information can call the same number."
000818
ATN34902

Copyright © 2000 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .